Trimipramine Pharmacogenetics - Genetic Drug Testing Gene2Rx

Drug Overview

Trimipramine (brand name Surmontil) is a tricyclic antidepressant used to help manage mood disorders. It is one of the older classes of antidepressants and is less commonly prescribed than newer agents but remains an option when first-line treatments are not effective or tolerated.

It's primarily used for major depressive disorder and sometimes off-label for insomnia. The drug blocks reuptake of serotonin and norepinephrine, leaving more of both available between nerve cells; the antihistamine activity is what makes it sedating.

Trimipramine works by inhibiting transport proteins that clear neurotransmitters from the synaptic space, which increases the availability of serotonin and norepinephrine. It also has some antagonism at histamine and muscarinic receptors, which can contribute to sedation and certain side effects.

Relevant Genes and Their Roles

Two liver enzymes break trimipramine down: CYP2D6 and CYP2C19. CYP2D6 converts it into less active metabolites, while CYP2C19 handles the conversion of the tertiary amine into secondary amines. Variants in either one change how fast the drug is cleared.

Genetic differences (called polymorphisms) can lead to categories such as poor or ultra-rapid metabolizers. A “poor metabolizer” has less active enzyme and may clear trimipramine slowly, raising drug levels and side effect risk. An “ultra-rapid metabolizer” has highly active enzyme and may clear the drug too quickly, reducing its effectiveness.

Impact of Genetics on Drug Response

Depending on whether someone is an ultra-rapid, rapid, normal, intermediate or poor metabolizer of CYP2D6 or CYP2C19, trimipramine levels can be lower or higher than expected. Rapid metabolizers may have sub-therapeutic concentrations and a higher risk of treatment failure, while poor metabolizers may accumulate the drug and experience more side effects or toxicity.

Expected Clinical Effects of Genetic Variation

Ultrarapid/Rapid Metabolizer

Effect on drug levels: Increased clearance leads to lower blood concentrations.
Clinical consequence: Higher chance of treatment failure due to sub-therapeutic levels.
Side effects: Generally fewer side effects; efficacy may be reduced.

Normal Metabolizer

Effect on drug levels: Expected, standard pharmacokinetics.
Clinical consequence: Typical therapeutic response.
Side effects: Side effect risk as described in standard prescribing information.

Intermediate Metabolizer

Effect on drug levels: Moderately reduced clearance, higher than normal concentrations.
Clinical consequence: Increased probability of side effects.
Side effects: Mild to moderate side effects may be more frequent.

Poor Metabolizer

Effect on drug levels: Greatly reduced clearance, significantly higher concentrations.
Clinical consequence: High risk of adverse effects or toxicity.
Side effects: More severe side effects (e.g., anticholinergic effects, sedation) may occur frequently.

Indeterminate/Not Available

Effect on drug levels: Unknown.
Clinical consequence: No specific guidance; follow standard dosing with monitoring.
Side effects: Unknown; monitor for typical TCA adverse effects.

Dosing Guidelines

The following dosing guidelines are based on the available guidelines for trimipramine from the Clinical Pharmacogenetics Implementation Consortium (CPIC).

CYP2D6 Dosing Guideline

Phenotype	Clinical Consequence	Guideline Recommendation
Ultrarapid Metabolizer	Lower plasma concentrations may lead to treatment failure.	Avoid tricyclic use; consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider higher target dose and use therapeutic drug monitoring.
Normal Metabolizer	Expected metabolism and therapeutic response.	Initiate therapy with recommended starting dose.
Intermediate Metabolizer	Higher plasma concentrations may increase side effect risk.	Consider a 25% reduction of recommended starting dose and use therapeutic drug monitoring.
Poor Metabolizer	Markedly increased risk of side effects due to high plasma levels.	Avoid tricyclic use; consider alternative drug. If a TCA is warranted, consider 50% dose reduction and use therapeutic drug monitoring.
Indeterminate	Unknown impact.	Initiate therapy with recommended starting dose with clinical monitoring.
Not available	Unknown impact.	Initiate therapy with recommended starting dose with clinical monitoring.

CYP2C19 Dosing Guideline

Phenotype	Clinical Consequence	Guideline Recommendation
Ultrarapid Metabolizer	Lower active drug levels; possible reduced efficacy or altered side effects.	Avoid tertiary amine use; consider alternative drugs not metabolized by CYP2C19 (e.g., nortriptyline, desipramine). If a tertiary amine is warranted, use therapeutic drug monitoring.
Rapid Metabolizer	Lower active drug levels; possible reduced efficacy or altered side effects.	Avoid tertiary amine use; consider alternative drugs not metabolized by CYP2C19. If a tertiary amine is warranted, use therapeutic drug monitoring.
Normal Metabolizer	Expected metabolism and therapeutic response.	Initiate therapy with recommended starting dose.
Intermediate Metabolizer	Moderately reduced metabolism; slight increase in drug levels.	Initiate therapy with recommended starting dose.
Poor Metabolizer	Higher drug levels may increase side effect risk.	Avoid tertiary amine use; consider alternative drugs not metabolized by CYP2C19. For tertiary amines, consider 50% dose reduction and use therapeutic drug monitoring.
Likely Intermediate Metabolizer	Moderately reduced metabolism; slight increase in drug levels.	Initiate therapy with recommended starting dose.
Likely Poor Metabolizer	Higher drug levels may increase side effect risk.	Avoid tertiary amine use; consider alternative drugs not metabolized by CYP2C19. For tertiary amines, consider 50% dose reduction and use therapeutic drug monitoring.
Indeterminate	Unknown impact.	Initiate therapy with recommended starting dose with clinical monitoring.
Not available	Unknown impact.	Initiate therapy with recommended starting dose with clinical monitoring.

Alternative Treatment Options

Examples of alternative treatments from guidelines include TCAs not extensively metabolized by these enzymes, such as nortriptyline or desipramine, or choosing non-TCA antidepressants. These are guideline examples only and not specific medical advice.

Sources and References

CPIC – Guideline for Tricyclic Antidepressants and CYP2D6 and CYP2C19

Considering GeneSight for this medication?

Gene2Rx uses the same CPIC and FDA guidelines as GeneSight, covers more medications, costs $5-$49 instead of several hundred, and works with the 23andMe or AncestryDNA data you may already have. See the full side-by-side comparison before ordering.

Read the comparison →

Genes that affect Trimipramine

See the full list of drugs affected by each gene:

Brand names containing Trimipramine

See how your genetics affect each product Trimipramine shows up in:

Surmontil

Brand of trimipramine